Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Centessa Pharmaceuticals plc

Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
Centessa Announces Pricing of Initial Public Offering
From Centessa Pharmaceuticals plc
Via Business Wire
Tickers CNTA
Centessa Pharmaceuticals Announces Expansion of Management Team and Board of Directors
From Centessa Pharmaceuticals plc
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.